Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Quoin Pharmaceuticals  / Equity Bottom-Up

<ul><li>The FDA recently granted QRX003 Rare Pediatric Disease (RPD) Designation for the treatment of NS.</li><li>The European Medicines Agency earlier had granted Orphan Drug Designation to QRX003.</li><li>The company believes these designations reinforce the potential of QRX003 as a therapeutic candidate as it advances clinical studies towards a potential New Drug Application (NDA) for QRX003 as the first approved treatment for NS.</li></ul>

The FDA recently granted QRX003 Rare Pediatric Disease (RPD) Designation for the treatment of NS.The European Medicines Agency earlier had granted Orphan Drug Designation to QRX003.The company believes these designations reinforce the potential of QRX003 as a therapeutic candidate as it advances clinical studies towards a potential New Drug Application (NDA) for QRX003 as the first approved treatment for NS.

QNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate Timeline